The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment

Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a  synergistic antitumor effect in  preclinical models. This article presents the  results of  the  phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: B. Ya. Alekseev, I. M. Shevchuk, V. Р. Aleshin
Materialtyp: Artigo
Språk:Russo
Publicerad: Remedium Group LLC 2021-06-01
Serie:Медицинский совет
Ämnen:
axitinib
avelumab
metastatic renal cell carcinoma
pd-l1
sunitinib
Länkar:https://www.med-sovet.pro/jour/article/view/6209
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk